MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives $37.50 Average Price Target from Brokerages

Key Points

• MiNK Therapeutics, Inc. has received a consensus recommendation of "Moderate Buy" from five brokerages, with a reported average 1-year price target of $37.50.
• The company's latest earnings report showed a loss of ($1.06) EPS, which missed analysts' expectations by ($0.51).
• As of the latest data, MiNK Therapeutics shares are trading at $14.90, with a market cap of $67.35 million, and a 52-week range of $4.56 to $76.00.

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $37.50.

INKT has been the topic of several analyst reports. B. Riley upgraded shares of MiNK Therapeutics to a "strong-buy" rating in a research report on Friday, July 18th. Wall Street Zen downgraded shares of MiNK Therapeutics to a "strong sell" rating in a research report on Saturday, August 23rd. Zacks Research lowered shares of MiNK Therapeutics from a "hold" rating to a "strong sell" rating in a report on Monday, August 18th. HC Wainwright upgraded shares of MiNK Therapeutics from a "neutral" rating to a "buy" rating and set a $35.00 price objective for the company in a research note on Friday, August 15th. Finally, William Blair lowered shares of MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Friday, July 11th.

MiNK Therapeutics Stock Down 7.3%

Shares of INKT traded down $1.16 during trading hours on Friday, hitting $14.82. The company had a trading volume of 40,091 shares, compared to its average volume of 131,051. The firm has a market cap of $66.99 million, a price-to-earnings ratio of -5.15 and a beta of 0.33. The business has a fifty day moving average of $15.27 and a 200-day moving average of $10.54. MiNK Therapeutics has a 12 month low of $4.56 and a 12 month high of $76.00.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.51). On average, equities analysts expect that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.